Multi-omics Characteristics and Prognosis of Idiopathic Sudden Sensorineural Hearing Loss
Launched by DAN BING · Apr 9, 2024
Trial Information
Current as of November 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called idiopathic sudden sensorineural hearing loss (SSNHL), which is a type of hearing loss that happens suddenly and for reasons that are not clear. The researchers want to learn more about the biological factors related to this condition and how they might influence a person's recovery. They will compare patients with SSNHL to healthy individuals to see if there are differences in genetic information and MRI results. The goal is to find out what factors can help predict how well someone might recover from this type of hearing loss.
To be eligible to participate, individuals must be at least 4 years old and have a confirmed case of SSNHL, which means they have lost some hearing in one or both ears within the last 72 hours. Healthy individuals without any recent ear issues may also join as controls. Participants will undergo hearing tests, provide blood samples, and have imaging scans to help researchers gather important information. This study is not yet recruiting participants, but it aims to develop a model that could better predict outcomes for those affected by this hearing loss.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 4
- • Participants with SSNHL: unilateral or bilateral sensorineural hearing loss of \> 30 dB HL (decibel) involving at least 3 continuous test frequencies developing within 72 hours
- • Healthy controls: people with PTA thresholds of all test frequencies ≤ 20 dB HL and without otologic disease in the last 3 months
- • Completed informed consent and promised to finish follow-ups
- Exclusion Criteria:
- • Hearing loss with explicit causes, including noise-induced, Ménière's disease, ototoxicity exposure, mumps infection or history of syphilis infection and so on.
- • A history of head trauma or otologic surgery.
- • Malformation of temporal bone discovered by computed tomography (CT)
- • Retro-cochlear lesion discovered by magnetic resonance imaging (MRI)
- • Pregnant women
About Dan Bing
Dan Bing is a leading clinical trial sponsor dedicated to advancing medical research and innovation. With a robust portfolio in developing novel therapeutics, Dan Bing focuses on conducting high-quality clinical trials that adhere to stringent regulatory standards. The organization collaborates with healthcare professionals and research institutions worldwide to explore cutting-edge treatments across various therapeutic areas. Committed to patient safety and ethical research practices, Dan Bing strives to contribute significantly to the advancement of healthcare solutions that improve patient outcomes and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported